Dr. Krishnan Suthanthiran Receives Lifetime Achievement Award from CRT for Contributions to the Field of Brachytherapy
Washington, DC, USA – (EIN PRESSWIRE) – March 14, 2025
Krishnan Suthanthiran, President and Founder of TeamBest Global Companies and the Best Cure Foundation (BCF), received a lifetime achievement award from Cardiovascular Research Technologies (CRT) for his exceptional commitment to advancing and advocating in the field of brachytherapy, including vascular brachytherapy. A pioneer and inventor, he has collaborated with numerous leaders in this field (including vascular brachytherapy), saving tens of thousands of lives. The award was presented by Dr. Ron Waksman, Chairman of the CRT 2025 Conference, during the opening ceremonies held in Washington, DC, on March 8, 2025. Over 3,000 cardiologists and medical professionals attended, many of whom witnessed the ceremony. Suthanthiran is a healthcare professional who has devoted more than half a century to cheering, helping, and saving lives every day. Through his non-profit BCF, Suthanthiran plans to establish the first Best Cure non-profit, Pro Health Center and Medical Center, in the suburbs of Pittsburgh, Pennsylvania. The Pro Health Centers will be non-profit proactive, preventive, primary medical, dental, and eye care wellness centers. BCF also plans to establish BCF Medical Centers for Treatment (similarly non-profit), which will focus on all diseases as specialty medical centers and all centers operating 24/7.
It has been over 30 years since the first vascular brachytherapy (VBT) animal experiments and human clinical trials were performed and 24 years since the approval of VBT for human clinical use for the treatment of in-stent coronary artery restenosis by the US FDA on November 3, 2000. Dr. Paul Teirstein, who practices at Scripps Clinic in La Jolla, California, in collaboration with Virginia-based Best Medical International (BMI), began the first randomized, double-blind human clinical trials Phase 1 study using Iridium-192 seeds in nylon ribbons starting in 1994. At approximately the same time, Dr. Ron Waksman, at Emory University in Atlanta, Georgia, in collaboration with BMI, was conducting animal experiments using Iridium-192 seeds in nylon ribbons.
All the initial animal experiments and human clinical studies were conducted using BMI Iridium-192 seeds in nylon ribbons. The first Phase 1 study’s successful clinical results were published at the first Vascular Brachytherapy, VBT meeting, hosted by Dr. Ron Waksman and Emory University, in January 1996 at the JW Marriott Hotel in Atlanta, Georgia. Subsequently, the Novoste Corporation, located in Norcross, Georgia — which started conducting BetaCath clinical trials — began to conduct human clinical trials with Dr. Ron Waksman's assistance, for in-stent coronary artery restenosis and like the Scripps Clinic Phase 1 clinical trials, used Iridium-192 seeds in nylon ribbons manufactured and supplied by BMI. The human clinical trials Phase II studies by Cordis Corporation (located in Miami Lakes, Florida, a J&J company at the time) using BMI Iridium-192 seeds in nylon ribbons and by Novoste using Beta-Cath Device, were approved for in-stent coronary artery restenosis treatment by the US FDA at the same time — November 3, 2000.
BMI, using its affiliated company Best Vascular, Inc., purchased the Beta-Cath assets of Novoste Corporation on March 10, 2006, and continued to operate the same Novoste manufacturing facilities, but now under the name Best Vascular, Inc./Novoste. Best Vascular just celebrated its 19th anniversary. Best Vascular/Novoste continues to support and plans to expand the clinical uses of VBT. The company is currently seeking for its customers to help develop future applications of VBT and contribute to a new book on VBT, set to be published in 2026.
For more information, Click here to download the original press release.